Burnaby, BC Biotechnology and Pharmaceutical Companies Directory

Burnaby, BC Biotechnology and Pharmaceutical Companies directory and employer contacts list

The following Burnaby, BC, Canada Biotechnology and Pharmaceutical Companies are among the many key British Columbia organizations listed in the JobPro Directory.
Try JobPro today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.

Dr. Alex Berlin, Vice President of Research
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
ABerlin60@lignol.ca
info60@lignol.ca
www.lignol.ca

Dr. Berlin developed postdoctoral R&D work in biorefinery of lignocellulosics at the Forest Products Biotechnology Group, Faculty of Forestry, University of British Columbia (Vancouver, BC, Canada). He has more than 15 years of R&D experience in this area including expertise in substrate pretreatment technologies, enzymatic hydrolysis of lignocellulosics, carbohydrate fermentation into cellulosic ethanol and other products, and development of lignin-based high-added value co-products.

He has authored or co-authored more than 50 scientific publications and invention patents. Dr. Berlin has extensive international industrial experience in business development for the Eastern European, South and North American biotech markets (bio-ethanol, food, and enzyme technologies).

Dr. Peter Lutwyche, Vice President, Pharmaceutical Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infovo@inexpharm.com
www.tekmirapharm.com

Dr. Lutwyche joined Tekmira's subsidiary company, Protiva Biotherapeutics Inc., in February 2008, and has responsibility for manufacturing, process development and quality control for all Tekmira product candidates as well as supporting Tekmira's collaborative partners as they advance products based on Tekmira's technology.

Tekmira expects three siRNA product candidates using the company's SNALP delivery technology will be in clinical development in 2009.

Dr. Lutwyche joined Tekmira from QLT Inc., where he was employed for ten years, most recently as Director, Pharmaceutical Development. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous preclinical and clinical stage products.

Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.

Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you.

Try JobPro today for free for more contacts, real email addresses and detailed company information from this and over 80 other industries across British Columbia.

Add or update company & contact information, or send feedback to directory maintainers.

Top of page

Humphrey Tebit, Biopharmaceutics
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
HTebit01pat@cantest.com
cantest01pat@cantest.com
www.cantest.com

Rajender Kamboj, Ph.D., Executive Vice President, Drug Discovery
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
RKamboj4zbdj@xenon-pharma.com
info4zbdj@xenon-pharma.com
www.xenon-pharma.com

Rajender Kamboj, Executive Vice President, Drug Discovery joined Xenon in April 2002. Dr. Kamboj was previously the Vice President and Chief Scientific Officer of Allelix Biopharmaceuticals Inc. (part of NPS Pharmaceuticals, Inc) where he had primary responsibility for managing their drug discovery programs.

In his 12 years with Allelix/NPS, Dr. Kamboj managed research teams covering all aspects of drug discovery and development, from initial research to clinical trials.

Under his leadership at Allelix/NPS, Dr. Kamboj also established, implemented and managed significant corporate partnerships with Eli Lilly, Hoechst Marion Roussel (now Aventis) and Janssen Pharmaceutica (part of Johnson & Johnson).

He led the development of nine drug discovery programs in neurological, metabolic and other therapeutic areas. During his tenure, four drug development programs were independently advanced into clinical studies by Allelix/NPS and three programs partnered with Eli Lilly, Aventis and Johnson & Johnson were advanced into late-stage pre-clinical development. Dr. Kamboj received his PhD from the University of Adelaide in Australia.

Charles LeBlanc, Manager, Environmental Division
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
cleblancy@cantest.com
cantesty@cantest.com
www.cantest.com

Gurminder Minhas, Director, Technology Deployment
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800 X 115 - direct
Tel. 604 222-9800
Fax. 604 222-9801
GMinhash0la4@lignol.ca
infoh0la4@lignol.ca
www.lignol.ca

Gurminder Minhas is the former Head of Research for the Pulp and Paper Division of Canfor Corp. and has extensive experience in process implementation for new technologies, as well as plant performance and optimization.

Gwen Epstein, Lab Manager
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
life9052@lifebank.com
www.lifebank.com

As the Laboratory Manager of Lifebank; Gwen Epstein is responsible for supervising the laboratory operations of the cord blood bank, providing expertise in the development of laboratory procedures, training and ensuring compliance with the regulatory requirements of a cellular therapy laboratory.

Gwen graduated from the University of BC with a BSc, major in Microbiology and completed certification as a registered medical technologist with the CSMLS. Prior to the position at Lifebank; Gwen was the Coordinator of the Nucleic Acid Testing Lab and the HLA lab at the Canadian Blood Services. The experience in HLA typing was obtained through experience working in the Immunology Lab at VGH. Gwen just completed training as an assessor for the AABB.

Top of page

Tammy Mullarky, Vice President, Strategic Planning and Business Development
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
info85ar2@inexpharm.com
www.tekmirapharm.com

September 29, 2008 - Tammy Mullarky has joined Tekmira effective immediately and will have responsibility for strategic planning and business development including securing additional licensing and collaborative research and development agreements for Tekmira's technology.

Ms. Mullarky joined Tekmira from Targeted Growth, Inc. where as Senior Vice President she was responsible for business functions including business development, intellectual property and finance. Prior to Targeted Growth, Ms. Mullarky was a senior executive at Epigenomics, AG where she completed a $100 million diagnostics partnership.

Ms. Mullarky also has experience as a venture capital partner and was a founder and senior executive at AnorMed Inc. Before AnorMed, she was a member of the corporate mergers and acquisitions team for F. Hoffmann- La Roche. Ms. Mullarky has a M.A. in Science Management from the Massachusetts Institute of Technology and a B.A. in Chemistry from Whitman College.

Heather Harris-Harper, Director, Clinical Operations, CANTEST Clinical Research
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 734-7276
Fax. 604 731-2386
cantest4eoue58@cantest.com
www.cantest.com

January 30, 2007 - As Director, Clinical Operations, Ms. Harris-Harper's responsibilities include the direction, planning and execution of clinical trials, ensuring operational excellence for CANTEST Clinical Research's international corporate clientele.

Ms. Harris-Harper brings to CANTEST 20 years of experience in the conduct of pharmaceutical industry sponsored clinical trials and has held progressive positions in clinical trial monitoring, management and operational supervision at several leading multinational biotechnology and pharmaceutical companies.

Brent Hale, Director, Human Resources
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way
Burnaby, BC V5G 1K5
Tel. 604 639-8420 - direct
Tel. 604 734-7276
Fax. 604 731-2386
bhalebrr8@cantest.com
cantestbrr8@cantest.com
www.cantest.com

January 30, 2007 - CANTEST Ltd. is pleased to announce the addition of Brent Hale as Director, Human Resources at CANTEST.

In addition to his in-depth knowledge of employment and labour law matters, Mr. Hale has experience in all areas of HR including compensation, recruitment, communications, organizational and leadership development and change management.

Gayle Mills, Senior Vice President, Business Development
Amgen British Columbia Inc.
7990 Enterprise Street
Burnaby, BC V5A 1V7
Tel. 604 676-8300
Fax. 604 676-8349
investor.relationshhcksk6@amgen.com
www.abgenix.com

Tom Redelmeier, President and Chief Executive Officer
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 222-2548
Fax. 604 222-2563
info0o@northernlipids.com
www.northernlipids.com

Top of page

Liren Tang, Ph.D., Head of Life Science
Welichem Biotech Inc.
316 - 4475 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 432-1703
Fax. 604 432-1704
lirentangrp@welichem.com
inforp@welichem.com
www.welichem.com

Vinay Chhatre, Manager Sales & Business Development
Northern Lipids Inc.
8855 Northbrook Court
Burnaby, BC V5J 5J1
Tel. 604 638-5631 - direct
Tel. 604 222-2548
Fax. 604 222-2563
infoa05n@northernlipids.com
www.northernlipids.com

Mark Murray, Ph.D., President & Chief Executive Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
infoj1yj@inexpharm.com
www.tekmirapharm.com

See also
Mark Murray, Ph.D., President & Chief Executive Officer
Protiva Biotherapeutics Inc.
100 - 3480 Gilmore Way
Burnaby, BC V5G 4W7
Tel. 604 630-5063 - direct
Tel. 604 630-5061
Fax. 604 630-5103

informationj1yj@protivabio.com
www.protivabio.com

Dr. Mark Murray has led Protiva since its inception in the summer of 2000. Dr. Murray has over 25 years of experience in both the R&D and business development facets of the biotechnology industry.

He has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry he has successfully completed numerous and varied partnering deals, directed successful product development programs, been responsible for strategic planning programs, raised financing and executed extensive business development initiatives.

During his R&D career, Dr. Murray worked extensively on three programs that resulted in FDA approved drugs, including the first growth factor protein approved for human use, a program he led for several years.

Dr. Murray obtained his Ph.D. from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.

Michael J. Abrams, Ph.D., President & Chief Executive Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infol5wc@inimexpharma.com
www.inimexpharma.com

Dr. Abrams is the founding CEO of AnorMED, Inc and led that company as President and CEO for ten years. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for $580M. Prior to AnorMED, Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED.

Abrams has a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a BA in Chemistry from Bowdoin College. In 2009 he was a co-recipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.

Kent Toy, Director of Finance
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
KToyyeeflz52@lignol.ca
infoyeeflz52@lignol.ca
www.lignol.ca

Kent Toy has extensive finance and administration experience with a range of private and public technology companies, providing full financial reporting and project accounting management.

Top of page

Cathy Shevchuk, Operations Manager
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
cshevchukqfk2@silliker.com
http://canada.silliker.com
www.silliker.com

Raymond Ma, Vice President of Process Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
RMa1qp@lignol.ca
info1qp@lignol.ca
www.lignol.ca

Raymond Ma is a well rounded executive with extensive experience in operation, process design, project execution and technology management. He has successfully managed a variety of technology development projects throughout his professional career.

John R. North, Ph.D., Chief Operating Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
jnorthqr@inimexpharmaceuticals.com
infoqr@inimexpharma.com
www.inimexpharma.com

Dr. North led the early development of Inimex' IDR technology, serving as EVP of R&D in 2004 and then President and Chief Executive Officer 2005 to 2009. Prior to joining Inimex, he served as Sr. Vice President, Scientific Affairs and Chief Scientific Officer of QLT Inc.

Earlier in his career, Dr. North was Managing Director of Monotech Laboratories Ltd., Biotechnology Consultant at PA Technology Ltd. and spent 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, most recently as Head of Exploratory Development at Ipsen International in the U.K. Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.

Cathy Cardinall, Quality Assurance and Safety Manager
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
ccardinalls3gz@silliker.com
http://canada.silliker.com
www.silliker.com

Don Enns, President, Chief Executive Officer and Board Member
CANTEST Ltd. - Burnaby (div. of Maxxam Analytics International Corporation)
4606 Canada Way - Burnaby Life Sciences Centre
Burnaby, BC V5G 1K5
Tel. 604 639-2609 - direct
Tel 604 734-7276
Fax: 604 731-2386
dennsgq479@cantest.com
cantestgq479@cantest.com
www.cantest.com

Don has well over 20 years of laboratory management experience. He obtained his BSc from Trinity Western University and an MBA designation from the University of British Columbia.

He currently sits on the Boards of several local companies in the Life Sciences field and has been President of organizations including the Canadian Association for Environmental Analytical Laboratories (CAEAL) and the BC Water & Waste Association (BCWWA.)

Don has been instrumental in CANTEST's expansion into the European and Southeast Asian markets. His experience overseas includes laboratory consulting such as on new laboratory construction, business development and mergers & acquisitions.

Top of page

Dr. John Webster, President, Chief Executive Officer and Founder
Welichem Biotech Inc.
316 - 4475 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 432-1703
Fax. 604 432-1704
jwebster98pai@welichem.com
info98pai@welichem.com
www.welichem.com

Ross MacLachlan, President, Director and Chief Executive Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 107 - direct
Tel. 604 222-9800
Fax. 604 222-9801
RMacLachlaneup75@lignol.ca
infoeup75@lignol.ca
www.lignol.ca

MacLachlan has extensive experience in project financing, including a former role in corporate finance at Haywood Securities Inc. Mr. MacLachlan also has a successful track record in technology development and marketing, having worked successfully with Xerox Canada and Systems Auditing, a company which he founded.

MacLachlan has worked with companies in both the conventional and alternative energy sectors. He has been actively involved in raising capital for emerging technology companies and has acted as consultant or director for many of them.

Martin (Marty) McConnell, C.A., Chief Financial Officer
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infotz9@inimexpharma.com
www.inimexpharma.com

For the past five years Marty has worked with emerging high tech and Biotech companies as part-time CFO focused on strategic financial issues. For the prior 18 years he was CFO for two midsize public (TSX, Nasdaq) Canadian high tech companies, from 1993 to 2002 with Spectrum Signal Processing Inc. and from 1985 to 1993 at Epic Data International Inc. Mr. McConnell holds a B. Comm. from the University of British Columbia and is a Chartered Accountant.

Jimmy Chang, Division Vice President
Silliker Canada Co. / Silliker JR Laboratories ULC
12 - 3871 North Fraser Way
Burnaby, BC V5J 5G6
Tel. 604 432-9311
Fax. 604 432-7768
jchangpgx3jb7@silliker.com
http://canada.silliker.com
www.silliker.com

Harlan Lahti, Founder and Technical Consultant
SISU Enterprises Co. Inc.
104A - 3430 Brighton Avenue
Burnaby, BC V5A 3H4
Tel. 604 420-6610
Fax. 604 420-6640

www.sisu.com/sisu

Lahti, 66, is a holistic health pioneer in Canada, having founded Finlandia Pharmacy, a natural health product purveyor in 1975. Lahti travels extensively around the world and has taught students in many countries.

Top of page

Vijay Sondhi, Chief Financial Officer & Chief Operating Officer
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
vsondhia04t13@xenon-pharma.com
infoa04t13@xenon-pharma.com
www.xenon-pharma.com

Vijay Sondhi, Chief Financial Officer & Chief Operating Officer, joined Xenon in December 2004. Before joining Xenon, Mr. Sondhi spent 16 years in the high technology sector in Europe and the United States.

He held CFO and co-CEO positions with IXOS Software AG (subsequently acquired by Open Text Corporation) where he led the company's successful IPO on the NASDAQ and Frankfurt stock exchanges.
He was also CFO of Fidelio Software GmbH where he assisted in the sale of the company to MICROS Systems, Inc. Immediately prior to joining Xenon, Mr. Sondhi was Managing Director at Allianz Venture Partners, a EURO 300 million venture capital fund based in Munich.

He also served as a Venture Partner at Warburg Pincus in Europe. In addition, he has held several positions with Booz-Allen & Hamilton & SAP AG. Mr. Sondhi received an MBA from Columbia University, New York and a B.Sc. in Computer Science from the University of British Columbia, Vancouver.

Owen Granger, Chief Financial Officer and Director
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
life8at09j7@lifebank.com
www.lifebank.com

Mr. Granger received a B.A. (honors) from the faculty of Business Administration, Simon Fraser University, in 1981 and has been a Certified Management Accountant since 1986. From 1983 to date he has been employed in a variety of senior accounting and financial management positions for public enterprises. He has been a director and senior financial officer of companies listed on the TSE, TSX, NASDAQ and over-the-counter markets.

In addition, since 1989, he has been a director and the part-time secretary treasurer of WestBond Enterprises Corporation, a public company engaged in the manufacture of disposable paper and polyethylene products for the medical, airline and industrial markets.

Dr. E. Kendall Pye, PhD Biochem., Chief Scientific Officer, Director and founder
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
info4@lignol.ca
www.lignol.ca

Dr. Pye was for 16 years President and CEO, Repap Technologies Inc. and Vice-President, Science and Technology, Repap Enterprises Inc. (Montreal), where he oversaw the Alcell process from which the Lignol process has been developed. Previously, he was a tenured Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania.

He has over 35 years of experience in biotechnology research and consulting in both commercial and academic environments, and is currently engaged in the development of related commercial plants throughout the world. Dr. Pye is a founder and director of Lignol.

F. Ernest Stacey, President, Chief Executive Officer and Director
Lifebank Cryogenics Corporation
200 - 4475 Wayburne Drive
Burnaby, BC V5G 4X4
Tel. 604 738-2722
Fax. 604 738-2726
life9it@lifebank.com
www.lifebank.com

Mr. Stacey was Laboratory Manager at the Canadian Blood Services, BC and Yukon Center; previously he was the Clinical Laboratory Manager at the Vancouver Hospital, UBC Pavilion. Since 1975, he has been involved with a number of laboratories across Canada in the capacities of instruction, management, inspection and quality control specifically in the field of Hematology.

Michael Rushton, P.Eng., Chief Operating Officer
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
MRushtonvw7pt@lignol.ca
infovw7pt@lignol.ca
www.lignol.ca

Rushton is a chemical engineer and business executive with more than 25 years of experience in the development and commercialization of technology. Mr. Rushton started his career in the oil industry and has subsequently been involved in the supply of technology to the pulp and paper, metal smelting and chemical process industries.

Most recently, Mr. Rushton has been involved with emerging technology in the alternative energy sector where he was President and CEO of Membrane Reactor Technologies Ltd.

Top of page

Charles J. Cohen, Vice President, Discovery Research
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
CCohenith@xenon-pharma.com
infoith@xenon-pharma.com
www.xenon-pharma.com

February 6, 2008 - Xenon Pharmaceuticals, a drug discovery and development company, announced it has appointed Charles J. Cohen as Vice President, Discovery Research.

"We are delighted to welcome Charlie to the Xenon team" commented Simon Pimstone, Xenon's President and CEO. "Charlie brings a unique combination of drug discovery experience and leadership including in areas that are highly relevant to Xenon such as pain.

With a drug candidate for pain currently in clinical trials, and a backup compound expected to follow, we are certain that Charlie's background will be of great benefit to Xenon. In addition to his experience in the pain area, Charlie brings broad and diverse expertise which will be applicable to our multiple discovery and pre-clinical programs."

Dr. Cohen has spent the past approximately 25 years in the pharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals, Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions and has published widely in the area of pain and more broadly in cellular neuroscience and neurology. Dr. Cohen received his PhD in Biophysics and Theoretical Biology from the University of Chicago.

Oreola Donini, Ph.D., Senior Director, Preclinical R&D
Inimex Pharmaceuticals Inc.
8540 Baxter Place
Burnaby BC V5A 4T8
Tel. 604 225-2251
Fax. 604 225-2257
infoauj7@inimexpharma.com
www.inimexpharma.com

Dr. Donini has 10 years experience in drug discovery, optimization and development and has lead the discovery, selection and advancement of Inimex' lead drug candidate, IMX942.

Prior to joining Inimex, Dr. Donini was involved in drug discovery and development at Kinetek Pharmaceuticals, managing a key program with an external partner, as well as initiating and managing a team providing informatics analysis and support to the company at large. Dr. Donini received her PhD in Chemistry from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California, San Francisco.

Eros Roncaia, President
Sorin Group Canada Inc. - Mitroflow Division
5005 North Fraser Way
Burnaby, BC V5J 5M1
Tel. 604 412-5650
Fax. 604 412-5690
infolbd6r9@mitroflow.com
www.sorin-hv.com

Paul Hughes, Vice President, Corporate Development and Communications
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby, BC V5G 3L1
Tel. 604 222-9800 X 110 - direct
Tel. 604 222-9800
Fax. 604 222-9801
phughesm6l92ya@lignol.ca
infom6l92ya@lignol.ca
www.lignol.ca

Paul Hughes has extensive international experience and expertise within the alternative/renewable energy sector gained within North America, Europe and Asia.
Mr. Hughes has co-founded energy companies in Europe and North America, has led an energy company from start-up through to IPO and has successfully raised private equity within multiple energy technology companies.

Mr. Hughes has also held senior business development and corporate finance roles in the UK and US utilities. Mr. Hughes holds a BSc (Hons) in Business from Aston University, UK, an Executive MBA from Ashridge, UK and is a Chartered Accountant.

Ian Mortimer, Senior Vice President, Finance and Chief Financial Officer
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Burnaby, BC V5J 5J8
Tel. 604 419-3200
Fax. 604 419-3201
info6v5tz5nu@inexpharm.com
www.tekmirapharm.com

Top of page

Dr. William Armiger, Vice President, Lignin Application Development
Lignol Innovations Inc. (div. of Lignol Energy Corporation)
101 - 4705 Wayburne Drive
Burnaby BC V5G 3L1
Tel. 604 222-9800
Fax. 604 222-9801
WArmigern67bhl8@lignol.ca
infon67bhl8@lignol.ca
www.lignol.ca

Dr. Armiger has more than 25 years of experience in the specialty-chemicals, pharmaceutical, biotechnology and environmental-technology industries and is the former CEO and cofounder of BioChemInsights Inc.

He also has extensive experience developing, licensing and commercializing products and process technology for use in industrial biofuels and wastewater treatment. Prior to joining Lignol, Dr. Armiger was engaged as Vice President of Venture Catalysts and also previously held senior consulting positions with The Catalyst Group and Arthur D. Little (“ADL").

Dr. Simon Pimstone, MD, PhD, FRCPC, President, Chief Executive Officer and Co-Founder
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Tel. 604 484-3300
Fax. 604 484-3445
SPimstoneyk2fyd@xenon-pharma.com
infoyk2fyd@xenon-pharma.com
www.xenon-pharma.com

Xenon was launched in 1998 by Dr. Pimstone, a South African-born internal medicine specialist who trained with the department of medical genetics at the University of B.C, and chief scientific officer Michael Hayden, a professor of genetics at UBC. They describe Xenon as a clinical genetics-based drug discovery company.

"We believe Xenon has identified more disease-relevant genes, 17 to date, than any other company in the world, and we have advanced a number of those discoveries into drug programs," Pimstone said.

Simon Pimstone is a founder, Director, and President & Chief Executive Officer at Xenon Pharmaceuticals Inc. Dr. Pimstone received his MD from the University of Cape Town.

He is an internal medicine specialist (FRCPC) with an interest in cardiovascular disease. Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD through the University of Amsterdam in cardiovascular genetics.

Dr. Pimstone has served as a consultant physician at the St. Paul's Hospital Lipid Clinic in Vancouver, as a Director of the Providence Healthcare Research Trust, a Director of the AllerGEN National Centre of Excellence, an Advisory Member of the SFU Biotech MBA program, and he is a Director of BIOTECanada. Dr. Pimstone is a member of the Young Presidents' Organization.

In 2005, he received the Business in Vancouver Top 40 under 40 Award and the Globe & Mail's Canadian Top 40 Under 40 Award in 2004. Dr. Pimstone is the author of numerous peer-reviewed publications and is also a regular guest speaker at international scientific meetings and healthcare conferences.

Brian Edgar, President
SISU Enterprises Co. Inc.
104A - 3430 Brighton Avenue
Burnaby, BC V5A 3H4
Tel. 604 420-6610
Fax. 604 420-6640

www.sisu.com/sisu

Edgar is also President of Dome Ventures Corporation, which owns SISUS Enterprises. He is also a director of the Pender Growth Fund Inc.

Brian Edgar has been active in public markets for two decades. A graduate of University of British Columbia law school, Mr. Edgar spent his early career as an associate with the firm of Rand, McLaughlin, Gorham & Tolmie, specializing in securities and corporation law.

Burnaby, BC Biotechnology and Pharmaceutical Companies directory and employer contacts list

Make your "cold calls" warmer